Detail akcie PixarBio Rg online

Business Summary: PixarBio Corporation, formerly BMP Holdings Inc., is a specialty pharmaceutical/biotechnology company. The Company is focused on pre-clinical and commercial development of neurological drug delivery systems for post-operative pain. It researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson's disease, and spinal cord injury. Its lead product platform, NeuroRelease, is a morphine replacement, and non-addictive pain platform for the surgical/hospital setting, for the battlefield, or for acute and chronic pain. The NeuroRelease effects sensory signals. NeuroRelease pain platform also includes 4-8 hour, three-day, seven-day, 14-day and 90-Day pain treatments. NeuroRelease is biodegradable, and it is non-toxic so it can be re-injected to extend treatment timelines. Its Injectable NeuroScaffold is a platform to advance from acute neuro-protective spinal cord injury treatment to a regeneration treatment for chronic spinal cord injury.
Financial Summary: BRIEF: For the nine months ended 30 September 2016, Pixarbio Corp revenues decreased 25% to $57K. Net loss increased 84% to $138K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative expenses increase of 44% to $130K (expense), Payroll Expense increase of 7% to $65K (expense).